ATS/Smith & Nephew
This article was originally published in The Gray Sheet
Executive Summary
Equity ownership position in Advanced Tissue Sciences by S&N more than doubles to about 8% with the conversion of a $10 mil. loan into about 2.8 mil. common stock shares. The loan was originally made in connection with a joint venture for development of Dermagraft tissue engineering technology for diabetic foot ulcers
You may also be interested in...
Smith & Nephew Buys Wound Care Line, Looks To Streamline Operations
Smith & Nephew's bid to bolster its medical device businesse involves a three-pronged strategy to acquire an advanced wound care product, divest its consumer businesses, and form a joint venture for its traditional wound care products.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.